Influenza treatment and prophylaxis with neuraminidase inhibitors: a review

Clicks: 257
ID: 6409
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #1,338 of 1,693 articles by views in Infection and drug resistance

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,693 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Influenza treatment and prophylaxis with neuraminidase inhibitors: a review Amanda Kamali,1 Mark Holodniy1,21Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA, USA; 2Office of Public Health, Department of Veterans Affairs, Washington, DC, USAAbstract: Influenza virus is a pathogen that causes morbidity and mortality worldwide. Whereas vaccination is important for prevention of disease, given its limitations, antiviral therapy is at the forefront of treatment and also plays a role in prevention. Currently, two classes of antiviral medications, the adamantanes and the neuraminidase inhibitors, are approved for treatment. Given the resistance patterns of circulating influenza, adamantanes are not recommended. Within the US, two neuraminidase inhibitors are currently approved for both treatment and prevention, while worldwide there are four available. In this review, we will briefly discuss the epidemiology and pathology of influenza and then discuss neuraminidase inhibitors: their mechanism of action, resistance, development, and future applications.Keywords: influenza, antiviral, neuraminidase, resistance
Reference Key
amanda2013influenzainfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Amanda Kamali, Mark Holodniy
Are you one of these authors? Claim your profile
Journal Infection and drug resistance
Year 2013
DOI
10.2147/IDR.S36601
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.